Trials / Withdrawn
WithdrawnNCT02516774
A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers
A Phase I Trial Assessing Adalimumab (Humira®), a Tumor Necrosis Factor α Inhibitor Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The hypothesis is that the particular richness of ATC's microenvironment in TAMs creates a unique opportunity for using Tumor Necrosis Factor blockade during chemotherapy and radiotherapy in order to counteract tumor resistance to therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Adalimumab |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2015-08-06
- Last updated
- 2016-01-26
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02516774. Inclusion in this directory is not an endorsement.